What is Lipocine's market cap?

Lipocine (LPCN) has a market capitalization of $17.6M and trades on NASDAQ.

Who are Lipocine's competitors?

Lipocine's key competitors include AbbVie Inc., Bausch Health, Praxis Precision Medicines, and others. These companies compete in similar markets and product categories.

Who does Lipocine partner with?

Lipocine's notable partners include Verity Pharmaceuticals, Inc., SPC Korea Limited, Aché Laboratórios Farmacêuticos, and others.

Where is Lipocine headquartered?

Lipocine is headquartered in United States of America and employs approximately 17 people. It has been publicly traded since 2012.

Lipocine

LPCN

Lipocine Inc. is a biopharmaceutical company that utilizes a proprietary lipid-based drug delivery technology platform to develop oral versions of molecules that are typically difficult to deliver.

Market cap

$17.64M-1.0%

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$1.2MBeat by $1.0M EPS-$0.54Miss by $0.03

Read the full report

Next report

Aug 4, 2026 (In 6 days)

Revenue estimate$213.0K

EPS estimate-$0.40

Competitors

By market cap

AbbVie$453.91B+36.3%

Praxis Precision Medicines, Inc.$8.8B+677%

Viking Therapeutics$4.0B+8.4%

Bausch Health Companies$1.7B-34.3%

Minerva Neurosciences$195.9M+1,234%

Lipocine$17.6M-2.9%

Cyclerion Therapeutics$15.2M+53.1%

Oragenics$2.3M+99.1%

By revenue growth

AbbVie+9.5%

Bausch Health Companies+8.2%

By net margin

AbbVie5.79%-1.5pp

Bausch Health Companies-1.88%-9.1pp

Praxis Precision Medicines, Inc.-3,658.53%—

Profile

Lipocine Inc. is a biopharmaceutical company that utilizes a proprietary lipid-based drug delivery technology platform to develop oral versions of molecules that are typically difficult to deliver. The company focuses on creating differentiated treatments for central nervous system (CNS) disorders, liver disease, and hormone supplementation. Its core value proposition lies in improving patient compliance and safety by replacing injectable or topical therapies with effective oral alternatives.

Competitive position

Lipocine is a specialized developer of oral drug delivery technologies, currently transitioning from a pure R&D entity to a royalty-earning company through strategic regional licensing of its approved TRT product.

GeographiesUnited States, Canada, South Korea, Brazil, Gulf Cooperation Council

Customer segmentsPharmaceutical Companies, Patients

Business modelLicensing and Royalties, Research and Development

SuppliersContract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs), Raw material suppliers for lipidic compositions

CustomersRegional pharmaceutical licensees, Specialty pharmacies, Wholesale drug distributors

CountryUnited States of America

Listed2012

Employees17.0

CEOMahesh V. Patel

SectorHealthcare

IndustryBiotechnology

Websitelipocine.com

FilingsSEC EDGAR

Questions, answered.

What is Lipocine's market cap?: Lipocine (LPCN) has a market capitalization of $17.6M and trades on NASDAQ.
Who are Lipocine's competitors?: Lipocine's key competitors include AbbVie Inc., Bausch Health, Praxis Precision Medicines, and others. These companies compete in similar markets and product categories.
Who does Lipocine partner with?: Lipocine's notable partners include Verity Pharmaceuticals, Inc., SPC Korea Limited, Aché Laboratórios Farmacêuticos, and others.
Where is Lipocine headquartered?: Lipocine is headquartered in United States of America and employs approximately 17 people. It has been publicly traded since 2012.